Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: A center for international blood and marrow transplant research-eurocord analysis

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 816-822

  Weisdorf, Daniel ^a,b   Eapen, Mary ^b   Ruggeri, Annalisa ^c,d   Zhang, Mei Jie ^b,c   Zhong, Xiaobo ^b   Brunstein, Claudio ^a   Ustun, Celalettin ^a   Rocha, Vanderson ^c,e   Gluckman, Eliane ^c,f  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Acute myeloid leukemia; Allogeneic transplantation; Umbilical cord blood; Unrelated donors

Indexed keywords

CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; EUROPE; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH CARE FACILITY; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; REMISSION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; UNRELATED DONORS; AGE; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROCEDURES;

AGE FACTORS; AGED; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84899907330     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.02.020     Document Type: Article

References (44)

1. Deschler B., Binek K., Ihorst G., et al. Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:967-975.
2. Devine S., Owzar K., Blum W., et al. A phase II study of allogeneic transplantation for older patients with AML in first complete remission using a reduced intensity conditioning regimen: results from CALGB 100103/BMT CTN 0502. Blood 2012, 120. [Abstract 230].
3. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007, 25:1908-1915.
4. Wong R., Giralt S.A., Martin T., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003, 102:3052-3059.
5. Farag S.S., Maharry K., Zhang M.J., et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011, 17:1796-1803.
6. Koreth J., Aldridge J., Kim H.T., et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 2010, 16:792-800.
7. Kurosawa S., Yamaguchi T., Uchida N., et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant 2011, 17:401-411.
8. Majhail N.S., Brunstein C.G., Shanley R., et al. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant 2012, 47:494-498.
9. Uchida N., Wake A., Takagi S., et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant 2008, 14:583-590.
10. Appelbaum F.R. Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation. Leukemia 2005, 19:171-175.
11. Barrett A.J., Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006, 20:1661-1672.
12. Finke J., Nagler A. Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning - is there still an upper age limit? A focus on myeloid neoplasia. Leukemia 2007, 21:1357-1362.
13. Lazarus H.M., Rowe J.M. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 2006, 20:1673-1682.
14. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
15. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haematopoietic stem-cell transplantation in adults with acute leukemia: a retrospective analysis. Lancet Oncol 2010, 11:653-660.
16. Brunstein C.G., Eapen M., Ahn K.W., et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012, 119:5591-5598.
17. Mohty M., de Lavallade H., Padaique P., et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor versus no donor comparison. Leukemia 2005, 19:916-920.
18. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006, 20:322-328.
19. Shimoni A., Kroger N., Zabelina T., et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005, 19:7-12.
20. Alousi A.M., Le-Rademacher J., Saliba R.M., et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. Blood 2013, 121:2567-2573.
21. Scaradavou A., Brunstein C.G., Eapen M., et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2013, 121:752-758.
22. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
23. Flowers M.E., Kansu E., Sullivan K.M. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999, 13:1091-1112.
24. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
25. Klein J.P., Moeschberger M.L. Survival Analysis: Statistical methods for censored and truncated data 2003, Springer-Verlag, New York, NY. Second ed.
26. Cox D.R. Regression model and life tables. J R Stat Soc B 1972, 34:187-200.
27. Ustun C., Lazarus H.M., Weisdorf D. To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant 2013, 48:1497-1505.
28. Oran B., Weisdorf D.J. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012, 97:1916-1924.
29. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
30. Becker H., Marcucci G., Maharry K., et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:596-604.
31. Frohling S., Schlenk R.F., Kayser S., et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006, 108:3280-3288.
32. Gardin C., Turlure P., Fagot T., et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007, 109:5129-5135.
33. Giles F.J., Borthakur G., Ravandi F., et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007, 136:624-627.
34. Itzykson R., Gardin C., Pautas C., et al. Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica 2011, 96:837-844.
35. Leith C.P., Kopecky K.J., Godwin J., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89:3323-3329.
36. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
37. Middleton P.G., Taylor P.R.A., Jackson G., et al. Cytokine gene polymorphisms associated with severe acute-graft-versus-host disease in HLA-identical sibling transplants. Blood 1998, 92:3943-3948.
38. Lin M.-T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003, 349:2201-2210.
39. Dickinson A.M., Harrold J.L., Cullup H. Haematopoietic stem cell transplantation: can our genes predict clinical outcome?. Expert Rev Mol Med 2007, 9:1-19.
40. Newell L.F., Gooley T., Hansen J.A., et al. Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. Biol Blood Marrow Transplant 2010, 16:1700-1706.
41. Xiao H., Cao W., Lai X., et al. Immunosuppressive cytokine gene polymorphisms and outcome after related and unrelated hematopoietic cell transplantation in a Chinese population. Biol Blood Marrow Transplant 2011, 17:542-549.
42. Peffault de Latour R., Brunstein C.G., Porhcer R., et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2013, 19:1355-1360.
43. Eapen M., Klein J.P., Sanz G.F., et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011, 12:1214-1221.
44. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010, 28:1878-1887.